TY - JOUR
T1 - Anthrax, toxins and vaccines
T2 - A 125-year journey targeting Bacillus anthracis
AU - Tournier, Jean Nicolas
AU - Ulrich, Robert G.
AU - Quesnel-Hellmann, Anne
AU - Mohamadzadeh, Mansour
AU - Stiles, Bradley G.
PY - 2009/3
Y1 - 2009/3
N2 - Bacillus anthracis is the causative agent of anthrax, a disease that plagues both humans and various animal species. Effective vaccines are available, but those approved for human use are crude culture supernatants that require multiple injections and a yearly boost. Many experts agree that it is now time for the next generation of human vaccines against anthrax. Accordingly, this review will succinctly focus upon: pathogenesis of B. anthracis, with particular emphasis upon the immune system; the pertinent biophysical nature of protective antigen, which includes how the protein toxin component affords protection as a vaccine target; alternative methods for improving protective antigen as an immunogen; and additional B. anthracis antigens that might further sustain protective titers in humans. In addition to a better understanding of the disease process elicited by B. anthracis, which will logically lead to better vaccines (and therapeutics), there also needs to be the same level of open-mindedness applied to the politics of anthrax.
AB - Bacillus anthracis is the causative agent of anthrax, a disease that plagues both humans and various animal species. Effective vaccines are available, but those approved for human use are crude culture supernatants that require multiple injections and a yearly boost. Many experts agree that it is now time for the next generation of human vaccines against anthrax. Accordingly, this review will succinctly focus upon: pathogenesis of B. anthracis, with particular emphasis upon the immune system; the pertinent biophysical nature of protective antigen, which includes how the protein toxin component affords protection as a vaccine target; alternative methods for improving protective antigen as an immunogen; and additional B. anthracis antigens that might further sustain protective titers in humans. In addition to a better understanding of the disease process elicited by B. anthracis, which will logically lead to better vaccines (and therapeutics), there also needs to be the same level of open-mindedness applied to the politics of anthrax.
KW - Anthrax
KW - Bacillus anthracis
KW - PA
KW - Pathogenesis
KW - Protective antigen
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=64049107159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=64049107159&partnerID=8YFLogxK
U2 - 10.1586/14787210.7.2.219
DO - 10.1586/14787210.7.2.219
M3 - Review article
C2 - 19254170
AN - SCOPUS:64049107159
VL - 7
SP - 219
EP - 236
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
SN - 1478-7210
IS - 2
ER -